Tilray: Schedule III Advances, But Cash Flow and Dilution Concerns Persist

What happened

Tilray's international medical cannabis revenue grew 34% with strong gains in Germany, UK, Poland, and Italy, reinforcing it as the primary growth driver. The U.S. regulatory landscape is improving, with Schedule III rescheduling moving forward, though final rule timing remains uncertain. However, GAAP profitability and free cash flow are still lacking, and the company continues to rely on equity issuance, leading to ongoing dilution. The stock trades at a low price-to-book ratio, but the master report's cautious WAIT rating reflects balanced risks from the hemp-THC ban and uncertain regulatory timelines. While the Seeking Alpha article argues the stock is a Buy, the underlying fundamentals have not yet demonstrated sustainable cash generation to support a high-conviction long.

Implication

Although international growth and Schedule III momentum are encouraging, Tilray has not achieved GAAP profitability or positive free cash flow, and its share count has ballooned, diluting existing holders. The upcoming hemp-derived THC ban in November 2026 remains a significant risk unless regulatory softening occurs. With the stock trading near $8.40 (as of early 2026), the risk/reward is balanced, and a more attractive entry would be closer to $7, consistent with the master report's analysis. Conversely, if the company delivers on its FY26 EBITDA guidance and achieves cash flow breakeven with further regulatory clarity, a re-rating toward $10-12 is possible. Until then, this remains a tactical rather than core holding.

Thesis delta

The new article corroborates the international cannabis growth story but does not materially change the investment thesis. Schedule III progress is incremental and still faces implementation delays, while the core concerns—lack of GAAP profitability, negative free cash flow, and rising share count—remain unaddressed. The master report's WAIT rating and balanced risk/reward framework are therefore unchanged.